Put Options on TCDA on 9/24/2020

Tricida, Inc., a pharmaceutical company (TCDA), focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD).

The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. 

Shares have broken all the supports as company's cash burn increases. Note that the $10 had acted as a support. This level now becomes an overhead resistance. We expect lowr prices for this stock.

Last Trade: $9.20

Trading Range: $8.76 to $44.30

Trade Buy 1 October $10.00 Put at $0.90 For a net debit of $0.90 Profit/Loss Analysis Breakeven at $9.10 Maximum profit is unbounded Maximum loss is ($90.00) at strike of $10.00 Closing Summary Sold 1 October $10.00 Put at $0.00

Position closed on 10/16/2020 at price of $0.00 with a -100.00% loss in 21 days.

Updates

10/16/2020 10:48:34 AM

TCDA put option closed

Back to Portfolio